Today 2026.10.08 D-End
Today 
|
Satellite Symposium 1 Sep. 18 (Fri), 08:30-09:00 |
Room C (2F) |
|
|---|---|---|
| Chair(s) | Sung-Yong Kim (Konkuk University School of Medicine, Korea) | |
Triple Targeting in Myelofibrosis with Momelotinib: An Integrated Therapeutic Approach via JAK1/2 and ACVR1 Inhibition
Soonchunhyang University Seoul Hospital, Korea
|
Satellite Symposium 2 Sep. 18 (Fri), 08:30-09:00 |
Room D (2F) |
|
|---|---|---|
| Chair(s) | Ki-Seong Eom (College of Medicine, The Catholic University of Korea, Korea) | |
Immune Reconstitution and Infection Prevention After CAR T-Cell and Bispecific Antibody Therapies: The Evolving Role of IVIG
Seoul National University College of Medicine, Korea
|
[OP01] Oral Presentation 5 |
Room A (1F) |
||
|---|---|---|---|
| Date & Time | Sep. 18 (Fri), 09:00-10:00 | ||
| Chair(s) |
Young Hoon Park (Ewha Womans University College of Medicine, Korea) Yu Ri Kim (Yonsei University College of Medicine, Korea) |
||
| Speaker(s) | 09:00-09:10 | Development of FcRH5 as a Therapeutic Target in B-Cell Lymphoma Jeonghwa Kim (Seoul National University College of Medicine, Korea) | |
| 09:10-09:20 | Longitudinal Whole-Exome Sequencing Revealed Early Clonal Suppression and Delayed Resistance Evolution in Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Ibrutinib Ho Cheol Jang (Chonnam National University Medical School, Korea) | ||
| 09:20-09:30 | Capturing the Landscape of Electronic Patient-Reported Outcomes during First-Line Lymphoma Therapy: A Multicenter Prospective Study Kunye Kwak (Korea University College of Medicine, Korea) | ||
| 09:30-09:40 | Real-World Outcomes of Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma (MEITL): A Taiwanese Multicenter Case Series Chiayu Chen (China Medical University Hospital, Taiwan) | ||
| 09:40-09:50 | Overcoming Poor Prognosis in Post-CAR-T Relapse: Potential Utility of Bispecific Antibodies and Allogeneic Hematopoietic Stem Cell Transplantation as Effective Salvage Strategies Gi June Min (College of Medicine, The Catholic University of Korea, Korea) | ||
| 09:50-10:00 | Prior Bruton Tyrosine Kinase Inhibitor Exposure Is Associated with Inferior Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed/Refractory Mantle Cell Lymphoma Tong-Yoon Kim (College of Medicine, The Catholic University of Korea, Korea) | ||
|
[OP02] Oral Presentation 6 |
Room B (1F) |
||
|---|---|---|---|
| Date & Time | Sep. 18 (Fri), 09:00-10:00 | ||
| Chair(s) |
Chul Won Choi (Korea University College of Medicine, Korea) Sung-Eun Lee (College of Medicine, The Catholic University of Korea, Korea) |
||
| Speaker(s) | 09:00-09:10 | Risk Stratification for Allogeneic Transplantation in Myelofibrosis: MTSS versus AlloRisk and the Impact of Driver Mutation Clearance Yu-Sung Chang (National Taiwan University Hospital, Taiwan) | |
| 09:10-09:20 | The Role of Pretransplant Cytoreductive Therapy in Patients with Chronic Myelomonocytic Leukemia Receiving Allogeneic Hematopoietic Stem Cell Transplantation Jin Zhang (Peking University People's Hospital, China) | ||
| 09:20-09:30 | Droplet Digital PCR Monitoring of JAK2V617F Complements Donor Chimerism after Allo-HSCT for Myelofibrosis So Yeon Park (College of Medicine, The Catholic University of Korea, Korea) | ||
| 09:30-09:40 | Linking Baseline Transcriptomics to Hematopoietic Recovery and Poor Graft Function after Allogeneic Transplantation for Myelofibrosis Daehun Kwag (College of Medicine, The Catholic University of Korea, Korea) | ||
| 09:40-09:50 | Haploidentical Hematopoietic Stem Cell Transplantation for Patients with Myelofibrosis: a Chinese Multicenter Retrospective Study Yuqian Sun (Peking University People's Hospital, China) | ||
| 09:50-10:00 | Clinico-Demographic and Hematological Characteristics of Patients with Polycythemia Vera: A Prospective Study in Tertiary Care Center in Nepal Suraj Aryal (Fishtail Hospital and Research Center Pvt Ltd, Nepal) | ||
|
[OP03] Oral Presentation 7 |
Room C (2F) |
||
|---|---|---|---|
| Date & Time | Sep. 18 (Fri), 09:00-10:00 | ||
| Chair(s) |
Ho-Young Yhim (Jeonbuk National University Medical School, Korea) Hyo Jung Kim (Hallym University College of Medicine, Korea) |
||
| Speaker(s) | 09:00-09:10 | Cost-Effectiveness of Autologous Stem Cell Transplantation in Multiple Myeloma Patients Aged 65-69 Years Jung Yeon Lee (College of Medicine, The Catholic University of Korea, Korea) | |
| 09:10-09:20 | One Thousand Autologous Stem Cell Transplants for Multiple Myeloma: Single Center, Retrospective Analysis Jun Ho Yi (Sungkyunkwan University School of Medicine, Korea) | ||
| 09:20-09:30 | Decoding the Role of TANGO1 in Myeloma Proteostasis and Therapeutic Vulnerability Ji Eun Lee (Yonsei University College of Medicine, Korea) | ||
| 09:30-09:40 | Long-Term Follow-Up of Busulfan plus Cyclophosphamide and Etoposide versus High-Dose Melphalan as Conditioning in Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma Sungnam Lim (Inje University College of Medicine, Korea) | ||
| 09:40-09:50 | Impact of Acute GVHD and Delayed Hematopoietic Recovery on the Incidence and Clinical Burden of Late Cytomegalovirus Reactivation and Disease after Letermovir Prophylaxis in CBT Naoki Okada (Kurashiki Central Hospital, Japan) | ||
| 09:50-10:00 | Clinical and Basic Studies of Anti-CD25 Monoclonal Antibody for the Prevention of Acute Graft-versus-Host Disease Yanfei Lu (The First Affiliated Hospital of Guangxi Medical University, China) | ||
|
[OP04] Oral Presentation 8 |
Room D (2F) |
||
|---|---|---|---|
| Date & Time | Sep. 18 (Fri), 09:00-10:00 | ||
| Chair(s) |
Jeong A Park (Inha University College of Medicine, Korea) Min Kyoung Kim (Yeungnam University College of Medicine, Korea) |
||
| Speaker(s) | 09:00-09:10 | Letermovir for Cytomegalovirus Prophylaxis after Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia Patients: Results of the LETreal Study Yi Xia (Peking University People's Hospital, China) | |
| 09:10-09:20 | Real-World Analysis of Belumosudil in Chronic Graft-versus-Host Disease: Early Progression May Reflect Ruxolitinib Discontinuation-Associated Flare Jae-Ho Yoon (College of Medicine, The Catholic University of Korea, Korea) | ||
| 09:20-09:30 | Not All High-Risk Features Are Created Equal: Organ- and Subtype-Specific Determinants of Non-Relapse Mortality in TA-TMA Seonghan Lee (College of Medicine, The Catholic University of Korea, Korea) | ||
| 09:30-09:40 | Targeting Steroid-Refractory Chronic GVHD with Reduced-Dose Rituximab Biosimilar (Truxima): A Phase 2 Prospective Study Eunice Jinsol Lee (College of Medicine, The Catholic University of Korea, Korea) | ||
| 09:40-09:50 | Letermovir Prophylaxis Real World Data on Cytomegalovirus Reactivation in Paediatric Haematopoietic Stem Cell Transplantation Recipients: A Single-Centre Experience Krithika Krishnakumar (Apollo Cancer Center, India) | ||
| 09:50-10:00 | Hyperacute Fatal Transplant-Associated Thrombotic Microangiopathy with Catastrophic Central Nervous System Involvement after HLA-Matched Sibling Transplantation for Severe Aplastic Anemia Moeko Hino (Chiba University Hospital, Japan) | ||
|
Joint Symposium 3 (East Asia Collaborative Session) The CAR-T Landscape in East Asia: Approvals, Coverage, Domestic Development, and Regulatory Frameworks for Cell and Gene Therapy Sep. 18 (Fri), 10:10-11:50 |
Room A (1F) |
|
|---|---|---|
| Chair(s) |
Hyeon-Seok Eom (National Cancer Center, Korea) Su-Peng Yeh (China Medical University Hospital, Taiwan) |
|
Insights into the Development of Cellular Therapy in China: Current Landscape and Future Directions
National Clinical Research Center for Hematologic Disease, China
Chimeric Antigen Receptor T-Cell Therapy for Lymphoma in Korea: Current Status, Challenges, and Future Directions
University of Ulsan College of Medicine, Korea
Unlocking Access of CAR-T Therapy in Taiwan: From Dual-Track Regulatory Transformation to National Insurance Breakthroughs
National Taiwan University Cancer Center, Taiwan
Current Status and Challenges of CAR-T Cell Products in Japan: A Regulatory Perspective
Pharmaceuticals and Medical Devices Agency, Japan
|
Scientific Session 5 AML/MDS Biology Sep. 18 (Fri), 10:10-11:40 |
Room B (1F) |
|
|---|---|---|
| Chair(s) |
Hawk Kim (Ewha Womans University College of Medicine, Korea) Chul Won Jung (Sungkyunkwan University School of Medicine, Korea) |
|
Leukemic Stem Cells in AML: Mechanisms, Detection, and Therapeutic Targeting
New York University Grossman School of Medicine, USA
Single-Cell Genomics for Predicting and Dissecting Venetoclax Resistance in Monocytic AML
Moffitt Cancer Center & Research Institute, USA
Information-Driven Studies on AML
College of Pharmacy, Seoul National University, Korea
|
Scientific Session 6 Potential Role of AI in Hematology and Cellular Therapy Sep. 18 (Fri), 10:10-11:40 |
Room C (2F) |
|
|---|---|---|
| Chair(s) |
Yoo Jin Kim (College of Medicine, The Catholic University of Korea, Korea) Jae-Yong Kwak (Jeonbuk National University Medical School, Korea) |
|
AI-Driven Prediction of Transplant Outcomes
University Hospitals Bochum and Essen, Germany
AI-Based Prediction of Early Relapse after CAR-T Therapy
University of California, San Francisco, USA
Clinical Relevance of BM Fibrosis in MDS Using Digital Imaging Approaches
Seoul National University College of Medicine, Korea
|
Education Session 2 Toxicities of Transplant and Immunotherapy Sep. 18 (Fri), 10:10-11:40 |
Room D (2F) |
|
|---|---|---|
| Chair(s) |
Hyoung Jin Kang (Seoul National University College of Medicine, Korea) Hyeon Jin Park (National Cancer Center, Korea) |
|
Autoimmune Cytopenia and Pure Red Cell Aplasia after HSCT
Seoul National University College of Medicine, Korea
Best Anti-Fungal Prophylaxis and Treatment Pre-/Post-HSCT
The Catholic University of Korea, Korea
Management of CAR T Toxicities – Expert Opinion
Children's Hospital of Philadelphia, USA
|
Luncheon Symposium 4 Sep. 18 (Fri), 12:00-12:40 |
Room A (1F) |
|
|---|---|---|
| Chair(s) | Byung Sik Cho (College of Medicine, The Catholic University of Korea, Korea) | |
How Deep Responses Translate into Transplant Success and Long-Term Survival in Secondary AML
Seoul National University College of Medicine, Korea
|
Luncheon Symposium 5 Sep. 18 (Fri), 12:00-12:40 |
Room C (2F) |
|
|---|---|---|
| Chair(s) | Kihyun Kim (Sungkyunkwan University School of Medicine, Korea) | |
Unlocking the Clinical Value of Early CAR-T Therapy in Multiple Myeloma: Insights from the CARTITUDE-4 Experience
Seoul National University College of Medicine, Korea
|
Luncheon Symposium 6 Sep. 18 (Fri), 12:00-12:40 |
Room D (2F) |
|
|---|---|---|
| Chair(s) | Nack-Gyun Chung (College of Medicine, The Catholic University of Korea, Korea) | |
CMV Prophylaxis in Pediatric HSCT: An Update on Evidence and Clinical Practice
Sungkyunkwan University School of Medicine, Korea
|
Joint Symposium 4 (ISCT-KSBMT) Next-Generation Immune Cell Therapies Beyond CAR-T Sep. 18 (Fri), 13:00-14:30 |
Room A (1F) |
|
|---|---|---|
| Chair(s) |
Je-Jung Lee (Chonnam National University Medical School, Korea) William Hwang (National Cancer Centre Singapore and Singapore General Hospital, Singapore) |
|
Beyond CAR-T: Next-Generation Immune Cell Therapies and New Manufacturing Paradigms
National Cancer Centre Singapore and Singapore General Hospital, Singapore
Fine-Tuning Signal Strength in CD5 CAR-NK Cells for Targeted T Cell Cancer Therapy
College of Pharmacy, Yonsei University, Korea
Multispecific T Cell Engagers, γδ T Cells, and NK Cell–Based Immunotherapy
University of Ulsan College of Medicine, Korea
|
Scientific Session 7 Expanding CAR T-Cell Therapy beyond Lymphoid Malignancies: Myeloid Neoplasms, Solid Tumors, and Autoimmune Diseases Sep. 18 (Fri), 13:00-14:30 |
Room B (1F) |
|
|---|---|---|
| Chair(s) |
June-Won Cheong (Yonsei University College of Medicine, Korea) Sung-Hyun Kim (Dong-A University College of Medicine, Korea) |
|
Clinical Translation of Next-Generation Cellular Therapies for Acute Myeloid Leukemia: From Clinical Proof-of-Concept to Hematopoietic Stem Cell–Sparing Immunotherapy
Memorial Sloan Kettering Cancer Center, USA
Enhanced CAR-T Cell Therapy Using Novel Gene Modifications
Seoul National University College of Medicine, Korea
Deep B Cell Depletion beyond Hematology: Immune Reset as a New Treatment Paradigm for Autoimmune Diseases
Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Germany
|
Nursing Session 1 KOR Multidisciplinary Approach to Hematopoietic Stem Cell Transplantation Patients I Sep. 18 (Fri), 13:00-14:30 |
Room C (2F) |
|
|---|---|---|
| Chair(s) | EunJung Joo (National Cancer Center, Korea) | |
Ocular Diseases in Hematopoietic Stem Cell Transplantation Patients: Key Indicators for Immediate Recognition
National Cancer Center, Korea
From Diagnostics to Intervention: Managing Infections in Hematology Patients Based on Imaging and Lab Results
College of Medicine, The Catholic University of Korea, Korea
|
Education Session 3 Practical Issues in Stem Cell Transplantation 2026 Sep. 18 (Fri), 13:00-14:30 |
Room D (2F) |
|
|---|---|---|
| Chair(s) |
Kyoung Ha Kim (Soonchunhyang University College of Medicine, Korea) Yong Park (Korea University College of Medicine, Korea) |
|
Recent Trends in Conditioning Regimens for Myeloid Malignancies
Chungnam National University College of Medicine, Korea
PTCy as a Universal Platform for GVHD Prophylaxis: Integrating New Standards and Defining the Remaining Role of ATG
Gregorio Marañón University General Hospital, Spain
Adult Cord Blood Transplantation Program for New Centers: A Practical Institutional Guide
Seoul National University College of Medicine, Korea
|
Presidential Symposium Lymphoma Cell Therapy Sep. 18 (Fri), 14:40-15:20 |
Room A (1F) |
|
|---|---|---|
| Chair(s) | Hyeon-Seok Eom (National Cancer Center, Korea) | |
Evolution of Cellular Therapies in Management of Lymphoma Patients
University of Pennsylvania, USA
|
Plenary Session 3 HSCT for Non-Malignant Disease Sep. 18 (Fri), 15:20-16:00 |
Room A (1F) |
|
|---|---|---|
| Chair(s) | Ho Joon Im (University of Ulsan College of Medicine, Korea) | |
Management of Mixed Chimerism and Graft Failure in Non-Malignant Diseases
Dana-Farber Cancer Institute, USA
|
Debate Session 1 KOR Allogeneic HSCT in Patients with AML or MDS with TP53 Alternation Sep. 18 (Fri), 16:50-17:40 |
Room A (1F) |
|
|---|---|---|
| Chair(s) | Joon Ho Moon (Kyungpook National University School of Medicine, Korea) | |
To Transplant
Chonnam National University Medical School, Korea
Not to Transplant
Yonsei University College of Medicine, Korea
|
Debate Session 2 KOR HSCT for HLH: Decreased Conditioning Intensity vs. Increased Conditioning Intensity Sep. 18 (Fri), 17:40-18:30 |
Room A (1F) |
|
|---|---|---|
| Chair(s) | Kyung-Nam Koh (University of Ulsan College of Medicine, Korea) | |
Reduced Intensity Conditioning
Seoul National University College of Medicine, Korea
Myeloablative Conditioning
Chonnam National University Hwasun Hospital, Korea
|
Joint Symposium 5 (JSTCT-KSBMT) EBV-Associated Diseases and HSCT: From CAEBV to Post-Transplant Complications Sep. 18 (Fri), 16:50-18:30 |
Room C (2F) |
|
|---|---|---|
| Chair(s) |
Nack-Gyun Chung (College of Medicine, The Catholic University of Korea, Korea) Takanori Teshima (Hokkaido University, Japan) |
|
EBV-Positive T/NK-Cell and B-Cell Lymphoproliferative Diseases: HSCT as Cure and as Complication
Sungkyunkwan University School of Medicine, Korea
Clinicopathological Spectrum of EBV-Positive T/NK-Cell Lymphoproliferative Diseases
Seoul National University College of Medicine, Korea
Post-Transplant Lymphoproliferative Disorder after Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, and Outcomes from Japanese Nationwide Data
Kameda Medical Center, Japan
A Japanese Registry-Based Analysis of Allogeneic Hematopoietic Stem Cell Transplantation for Adult Hemophagocytic Lymphohistiocytosis
Keio University, Japan
|
Scientific Session 8 Advances in HSCT Conditioning Sep. 18 (Fri), 16:50-18:20 |
Room D (2F) |
|
|---|---|---|
| Chair(s) |
Seong Kyu Park (Soonchunhyang University College of Medicine, Korea) Sang Kyun Sohn (Kyungpook National University School of Medicine, Korea) |
|
Conditioning Regimens for Allogeneic Hematopoietic Cell Transplantation in 2026
Fred Hutchinson Cancer Center, USA
Selection of Allogeneic Hematopoietic Progenitor Cell Donors
Memorial Sloan Kettering Cancer Center, USA
Optimal Conditioning in Autologous HSCT: Focus on Lymphoma
Seoul National University College of Medicine, Korea
